A Phase 3 interventional study of Estradiol and Placebo in Vulvovaginal Atrophy, Menopause and Dyspareunia, sponsored by TherapeuticsMD. Completed at 105 sites in 2 countries. Open to female participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-25.
Sponsored by TherapeuticsMD · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.
Among the 56 studies in Dyspareunia with a site in United States, this one is the 3rd largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2014, is one of 13 in phase 3, and was the 17th registered.
159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.
Browse Dyspareunia studies →8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:
University of Arizona · Sites in United States
Ages 40–90 · Women only · Healthy volunteers
Azure Biotech Inc. · Sites in United States
Ages 45–60 · Women only
Medstar Health Research Institute · Sites in United States
Ages 18+ · Women only
University Hospitals Cleveland Medical Center · Sites in United States
Ages 18–50 · Women only
Indiana University · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 40 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 14 · Phase 4 8
First in 2004; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 764 is above the median of 64 across 127 interventional studies indexed under Dyspareunia.
Median enrollment 60 across the 53 interventional studies, 200 across the 3 observational. Of the 38 that completed or were terminated, 20 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 56 have an industry lead sponsor. The 10 most frequent:
TherapeuticsMD is the lead sponsor of 6 studies on the registry; none are open to participants now.
TherapeuticsMD has 2 studies filed under Dyspareunia — fewer than ten, so there is no comparison to draw.
3 of the studies in Dyspareunia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197568Azure Biotech Inc.Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women | 2026-12-31 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06059586Indiana UniversityPre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 56 studies in Dyspareunia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of a new formulation of vaginal estradiol for the treatment of symptoms of vulvar and vaginal atrophy in postmenopausal women.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
female subjects between the ages of 40 and 75 years (at the time of randomization) with at least:
Exclusion Criteria:
Use of the following:
A history or active presence of medical disease that might confound the study or be detrimental to the subject, examples include:
Any clinically important abnormalities on screening physical exam, assessments, , or laboratory tests, such as:
Unresolved cervical cytologic smear report of atypical glandular cells of undetermined significance (AGUS) or atypical squamous cells of undetermined significance (ASCUS).
Cervical cytologic smear report of low-grade squamous intraepithelial lesion (SIL) or greater, CIN1 or greater, or any reported dysplasia; Subjects with ASCUS are eligible only if high risk human papilloma virus (HPV) result is negative.
In subjects with intact uterus: an endometrial biopsy report by one central pathologist at screening with one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Estradiol 4mcg Vaginal Softgel Capsule
Drug: Estradiol
Estradiol 10mcg Vaginal Softgel Capsule
Drug: Estradiol
Estradiol 25mcg Vaginal Softgel Capsule
Drug: Estradiol
Placebo Vaginal Softgel Capsule
Drug: Placebo
Co-Primary Efficacy Endpoint - Vaginal Superficial Cells
• Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells
• Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Vaginal pH
• Change from Baseline to Week 12 in vaginal pH as compared to placebo
Time frame: Baseline and 12 Weeks
Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia)
• Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Superficial Cells
• Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints- Vaginal Superficial Cells
Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Superficial Cells
Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Parabasal Cells
Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 2 in vaginal pH as compared to placebo
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 6 in vaginal pH as compared to placebo
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal pH
Change from Baseline to Week 8 in vaginal pH as compared to placebo
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia)
Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness)
Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation)
Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 2 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 6 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6
Time frame: Baseline to Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 8 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8
Time frame: Baseline to Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color)
Change from Baseline to Week 12 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity)
Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness)
Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3 Severity was assessed by the Investigator at Baseline and Week 2
Time frame: Baseline and Week 2
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 6
Time frame: Baseline and Week 6
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 8
Time frame: Baseline and Week 8
Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions)
Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 12
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score
Change from Baseline to Week 12 in FSFI Total Score as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal
Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire
Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication
Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm
Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain
Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction
Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
Time frame: Baseline and Week 12
PK Substudy - Hormone Concentration Assessments (Serum Estradiol, Estrone and Estrone Conjugates; SHBG)
Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG
Time frame: Pre-treatment, Day 2, Weeks 2 and 12
| Milestone | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Started | 191 | 191 | 190 | 192 |
| Completed | 175 | 174 | 177 | 178 |
| Not completed | 16 | 17 | 13 | 14 |
• Change from Baseline to Week 12 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal superficial cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| Co-Primary Efficacy Endpoint - Vaginal Superficial Cells | 17.50 ± 1.542 | 16.72 ± 1.540 | 23.20 ± 1.529 | 5.63 ± 1.537 |
• Change from Baseline to Week 12 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal parabasal cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| Co-Primary Efficacy Endpoint - Vaginal Parabasal Cells | -40.63 ± 1.755 | -44.07 ± 1.751 | -45.55 ± 1.745 | -6.73 ± 1.750 |
• Change from Baseline to Week 12 in vaginal pH as compared to placebo
| pH units | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| Co-Primary Efficacy Endpoint - Vaginal pH | -1.32 ± 0.066 | -1.42 ± 0.066 | -1.34 ± 0.066 | -0.28 ± 0.066 |
• Change from Baseline to Week 12 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| Co-Primary Efficacy Endpoint - Severity of Most Bothersome Symptom (Dyspareunia) | -1.52 ± 0.071 | -1.69 ± 0.071 | -1.69 ± 0.071 | -1.28 ± 0.070 |
• Change from Baseline to Week 2 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal superficial cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Superficial Cells | 31.35 ± 1.496 | 31.93 ± 1.488 | 38.85 ± 1.500 | 6.05 ± 1.498 |
Change from Baseline to Week 6 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal superficial cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints- Vaginal Superficial Cells | 18.41 ± 1.536 | 16.88 ± 1.543 | 22.65 ± 1.532 | 5.43 ± 1.525 |
Change from Baseline to Week 8 in the percentage of vaginal superficial cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal superficial cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Superficial Cells | 19.04 ± 1.561 | 17.41 ± 1.558 | 23.88 ± 1.554 | 5.98 ± 1.551 |
Change from Baseline to Week 2 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal parabasal cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Parabasal Cells | -40.23 ± 1.720 | -44.42 ± 1.710 | -45.60 ± 1.723 | -7.00 ± 1.720 |
Change from Baseline to Week 6 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal parabasal cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Parabasal Cells | -39.36 ± 1.750 | -43.55 ± 1.752 | -45.61 ± 1.746 | -9.23 ± 1.741 |
Change from Baseline to Week 8 in the percentage of vaginal parabasal cells (by vaginal cytologic smear) compared to placebo
| percentage of vaginal parabasal cells | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Parabasal Cells | -41.87 ± 1.768 | -43.78 ± 1.764 | -45.08 ± 1.762 | -7.86 ± 1.760 |
Change from Baseline to Week 2 in vaginal pH as compared to placebo
| pH units | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal pH | -1.23 ± 0.064 | -1.37 ± 0.064 | -1.30 ± 0.065 | -0.28 ± 0.064 |
Change from Baseline to Week 6 in vaginal pH as compared to placebo
| pH units | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal pH | -1.32 ± 0.066 | -1.40 ± 0.066 | -1.48 ± 0.066 | -0.30 ± 0.065 |
Change from Baseline to Week 8 in vaginal pH as compared to placebo
| pH units | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal pH | -1.35 ± 0.067 | -1.46 ± 0.067 | -1.45 ± 0.066 | -0.38 ± 0.066 |
Change from Baseline to Week 2 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | -0.99 ± 0.072 | -1.08 ± 0.072 | -1.02 ± 0.073 | -0.76 ± 0.072 |
Change from Baseline to Week 6 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | -1.30 ± 0.072 | -1.37 ± 0.072 | -1.48 ± 0.072 | -1.03 ± 0.070 |
Change from Baseline to Week 8 on the severity of the MBS of dyspareunia (vaginal pain associated with sexual activity) associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Most Bothersome Symptom (Dyspareunia) | -1.52 ± 0.073 | -1.64 ± 0.074 | -1.62 ± 0.075 | -1.15 ± 0.072 |
Change from Baseline to Week 2 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | -0.86 ± 0.066 | -1.01 ± 0.065 | -0.96 ± 0.066 | -0.72 ± 0.066 |
Change from Baseline to Week 6 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | -1.14 ± 0.067 | -1.27 ± 0.068 | -1.23 ± 0.067 | -0.90 ± 0.067 |
Change from Baseline to Week 8 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | -1.25 ± 0.069 | -1.44 ± 0.068 | -1.34 ± 0.068 | -1.01 ± 0.068 |
Change from Baseline to Week 12 on the severity of vaginal dryness associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Severity of Other VVA Symptoms (Vaginal Dryness) | -1.27 ± 0.068 | -1.47 ± 0.067 | -1.47 ± 0.067 | -0.97 ± 0.067 |
Change from Baseline to Week 2 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) | -0.47 ± 0.054 | -0.56 ± 0.053 | -0.51 ± 0.054 | -0.47 ± 0.054 |
Change from Baseline to Week 6 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) | -0.57 ± 0.055 | -0.64 ± 0.055 | -0.61 ± 0.055 | -0.55 ± 0.055 |
Change from Baseline to Week 8 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) | -0.74 ± 0.056 | -0.76 ± 0.056 | -0.73 ± 0.056 | -0.59 ± 0.056 |
Change from Baseline to Week 12 on the severity of vulvar and/or vaginal itching or irritation associated with VVA as compared to placebo VVA Symptoms Self-Assessment Questionnaire Severity Scale: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe. Subjects assessed severity at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Other VVA Symptoms (Vulvar and/or Vaginal Itching or Irritation) | -0.75 ± 0.055 | -0.81 ± 0.055 | -0.77 ± 0.055 | -0.60 ± 0.055 |
Change from Baseline to Week 2 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) | -0.69 ± 0.048 | -0.77 ± 0.047 | -0.78 ± 0.048 | -0.40 ± 0.047 |
Change from Baseline to Week 6 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) | -0.82 ± 0.049 | -0.93 ± 0.049 | -0.89 ± 0.049 | -0.50 ± 0.048 |
Change from Baseline to Week 8 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) | -0.98 ± 0.050 | -1.04 ± 0.050 | -0.99 ± 0.049 | -0.50 ± 0.049 |
Change from Baseline to Week 12 in Vaginal Color as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Color: No atrophy (pink) = 0; Mild (lighter in color) = 1; Moderate(pale in color) = 2; Severe (transparent/no color or inflamed) = 3 Severity was assessed by the Investigator at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Color) | -0.97 ± 0.049 | -1.06 ± 0.049 | -0.96 ± 0.049 | -0.60 ± 0.049 |
Change from Baseline to Week 2 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) | -0.85 ± 0.049 | -0.87 ± 0.049 | -0.93 ± 0.049 | -0.53 ± 0.049 |
Change from Baseline to Week 6 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) | -0.97 ± 0.051 | -1.02 ± 0.051 | -1.01 ± 0.051 | -0.61 ± 0.050 |
Change from Baseline to Week 8 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) | -1.03 ± 0.052 | -1.08 ± 0.051 | -1.08 ± 0.051 | -0.66 ± 0.051 |
Change from Baseline to Week 12 in Vaginal Epithelial Integrity as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Integrity: No atrophy (normal) = 0; Mild (vaginal surface bleeds with scraping) = 1; Moderate (vaginal surface bleeds with light contact) = 2; Severe (vaginal surface has petechiae before contact and bleeds with light contact) = 3 Severity was assessed by the Investigator at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Integrity) | -0.97 ± 0.051 | -1.07 ± 0.051 | -1.01 ± 0.050 | -0.60 ± 0.050 |
Change from Baseline to Week 2 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) | -0.76 ± 0.049 | -0.76 ± 0.049 | -0.76 ± 0.049 | -0.40 ± 0.049 |
Change from Baseline to Week 6 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) | -0.85 ± 0.051 | -0.93 ± 0.051 | -0.90 ± 0.050 | -0.53 ± 0.050 |
Change from Baseline to Week 8 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) | -0.96 ± 0.051 | -1.04 ± 0.051 | -0.99 ± 0.051 | -0.59 ± 0.051 |
Change from Baseline to Week 12 in Vaginal Epithelial Surface Thickness as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Epithelial Surface Thickness: No atrophy (rogation and elasticity of vault) = 0; Mild (poor rogation with some elasticity noted of vaginal vault) = 1; Moderate (smooth, some elasticity of vaginal vault) = 2; Severe \[smooth, no elasticity, constriction of the upper one third of vagina or loss of vaginal tone (cystocele and rectocele)\] = 3 Severity was assessed by the Investigator at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Epithelial Surface Thickness) | -0.98 ± 0.051 | -1.03 ± 0.051 | -0.94 ± 0.050 | -0.61 ± 0.050 |
Change from Baseline to Week 2 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain) = 3 Severity was assessed by the Investigator at Baseline and Week 2
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) | -0.79 ± 0.050 | -0.83 ± 0.050 | -0.86 ± 0.050 | -0.54 ± 0.050 |
Change from Baseline to Week 6 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 6
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) | -0.90 ± 0.051 | -0.95 ± 0.051 | -0.97 ± 0.051 | -0.60 ± 0.051 |
Change from Baseline to Week 8 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 8
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) | -1.00 ± 0.052 | -1.04 ± 0.052 | -1.06 ± 0.052 | -0.63 ± 0.052 |
Change from Baseline to Week 12 in Vaginal Secretions as compared to placebo Vaginal Mucosa Assessment Scale - Vaginal Secretions: No atrophy (normal clear secretions noted on vaginal walls) = 0; Mild (superficial coating of secretions, difficulty with speculum insertion) = 1; Moderate (scant not covering the entire vaginal vault, may need lubrication with speculum insertion to prevent pain) = 2; Severe (none, inflamed, ulceration noted, need lubrication with speculum insertion to prevent pain\] = 3 Severity was assessed by the Investigator at Baseline and Week 12
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Vaginal Mucosa Assessment (Vaginal Secretions) | -1.01 ± 0.051 | -1.06 ± 0.051 | -1.04 ± 0.051 | -0.64 ± 0.051 |
Change from Baseline to Week 12 in FSFI Total Score as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) - Total Score | 7.909 (6.748 to 9.070) | 9.431 (8.261 to 10.601) | 10.283 (9.133 to 11.434) | 7.458 (6.315 to 8.602) |
Change from Baseline to Week 12 in FSFI Domain Score (Arousal) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Arousal | 0.875 (0.657 to 1.093) | 1.287 (1.066 to 1.507) | 1.392 (1.176 to 1.608) | 0.93 (0.715 to 1.145) |
Change from Baseline to Week 12 in FSFI Domain Score (Desire) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Desire | 0.625 (0.471 to 0.779) | 0.800 (0.646 to 0.955) | 0.848 (0.695 to 1.000) | 0.630 (0.479 to 0.782) |
Change from Baseline to Week 12 in FSFI Domain Score (Lubrication) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Lubrication | 1.834 (1.578 to 2.090) | 2.242 (1.984 to 2.500) | 2.299 (2.045 to 2.553) | 1.595 (1.343 to 1.846) |
Change from Baseline to Week 12 in FSFI Domain Score (Orgasm) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Orgasm | 1.162 (0.903 to 1.421) | 1.274 (1.013 to 1.535) | 1.591 (1.334 to 1.847) | 1.202 (0.948 to 1.457) |
Change from Baseline to Week 12 in FSFI Domain Score (Pain) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Pain | 2.173 (1.879 to 2.467) | 2.548 (2.251 to 2.844) | 2.514 (2.222 to 2.805) | 1.930 (1.641 to 2.219) |
Change from Baseline to Week 12 in FSFI Domain Score (Satisfaction) as compared to placebo The FSFI is a brief, multidimensional questionnaire for assessing sexual function in women (Rosen et al., 2000). The questionnaire consists of 19 items that assess sexual function over the past 4 weeks and yield domain scores in six areas: sexual desire, arousal, lubrication, orgasm, satisfaction, and pain. The FSFI questionnaire has a minimum total score of 2.0, a maximum score of 36.0 points and was administered at Baseline and Week 12.
| units on a scale | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule |
|---|---|---|---|---|
| Secondary Efficacy Endpoints - Female Sexual Function Index (FSFI) Domain Score - Satisfaction | 1.257 (1.046 to 1.469) | 1.384 (1.170 to 1.597) | 1.629 (1.420 to 1.839) | 1.174 (0.965 to 1.383) |
Blood samples will be obtained from a subset of subjects at pre-selected sites to characterize PK parameters (AUC, tmax, Cmin, Cmax, Cavg) and to measure SHBG
Results for this outcome have not been posted.
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Estradiol 4mcg Vaginal Softgel Capsule | — | 0/191 (0%) | 46/191 (24.1%) |
| Estradiol 10mcg Vaginal Softgel Capsule | — | 3/191 (1.6%) | 41/191 (21.5%) |
| Estradiol 25mcg Vaginal Softgel Capsule | — | 4/190 (2.1%) | 45/190 (23.7%) |
| Placebo | — | 1/192 (0.5%) | 66/192 (34.4%) |
| Event | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/191 | 0/191 | 1/190 | 0/192 |
| AppendicitisGastrointestinal disorders | 0/191 | 0/191 | 1/190 | 0/192 |
| EndophthalmitisInfections and infestations | 0/191 | 0/191 | 1/190 | 0/192 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/191 | 0/191 | 1/190 | 0/192 |
| Sinus node dysfunctionCardiac disorders | 0/191 | 1/191 | 0/190 | 0/192 |
| Ankle fractureInjury, poisoning and procedural complications | 0/191 | 1/191 | 0/190 | 0/192 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/191 | 1/191 | 0/190 | 0/192 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/191 | 1/191 | 0/190 | 0/192 |
| Cervical myelopathyNervous system disorders | 0/191 | 0/191 | 0/190 | 1/192 |
| Event | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 12/191 | 14/191 | 6/190 | 15/192 |
| Vaginal dischargeReproductive system and breast disorders | 5/191 | 6/191 | 4/190 | 13/192 |
| NasopharyngitisInfections and infestations | 5/191 | 6/191 | 7/190 | 10/192 |
| Vulvovaginal pruritusReproductive system and breast disorders | 4/191 | 3/191 | 7/190 | 10/192 |
| Back painMusculoskeletal and connective tissue disorders | 9/191 | 1/191 | 4/190 | 8/192 |
| Urinary tract infectionInfections and infestations | 5/191 | 5/191 | 8/190 | 4/192 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/191 | 0/191 | 6/190 | 1/192 |
| Upper respiratory infectionInfections and infestations | 5/191 | 6/191 | 3/190 | 5/192 |
The modified intent to treat (MITT) population was the primary efficacy population, defined as all ITT subjects who received the treatment to which they were randomized, had baseline values for all co-primary variables, and had at least one post-baseline value for any of the four co-primary variables at any visit.
| Age, Categorical(Participants) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 148 | 162 | 156 | 151 | 617 |
| >=65 years | 43 | 29 | 34 | 41 | 147 |
| Age, Continuous(years) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Mean | 59.8 ± 5.90 | 58.5 ± 6.29 | 58.9 ± 6.26 | 59.3 ± 6.07 | 59.1 ± 6.14 |
| Sex: Female, Male(Participants) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Female | 191 | 191 | 190 | 192 | 764 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Canada | 13 | 10 | 15 | 12 | 50 |
| United States | 178 | 181 | 175 | 180 | 714 |
| Height(centimeters) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Mean | 162.7 ± 6.86 | 162.9 ± 6.93 | 162.3 ± 6.37 | 162.2 ± 6.30 | 162.5 ± 6.62 |
| Weight(kilograms) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Mean | 70.4 ± 14.26 | 71.1 ± 13.49 | 70.6 ± 13.7 | 70.4 ± 13.6 | 70.6 ± 13.74 |
| BMI(kg/m^2) | Estradiol 4mcg Vaginal Softgel Capsule | Estradiol 10mcg Vaginal Softgel Capsule | Estradiol 25mcg Vaginal Softgel Capsule | Placebo Vaginal Softgel Capsule | Total |
|---|---|---|---|---|---|
| Mean | 26.5 ± 4.87 | 26.8 ± 4.68 | 26.7 ± 4.79 | 26.7 ± 4.59 | 26.7 ± 4.73 |
Showing the first 100 of 105 sites across 2 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Estradiol
TherapeuticsMD